Psychosis in a 22-Year-Old Woman With Narcolepsy After Restarting Sodium Oxybate

Buckley, Patrick J.; Wolf, Chelsea T.

doi:10.1016/j.psym.2017.10.001

Cited by 8 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most similar cases we have found to this one were reported in 2011 and 2017. The first case 20 involved a 25-year-old female patient who exhibited bizarre behavior secondary to a psychotic presentation, which spontaneously remitted within 2 days during her hospital stay. Notably, in this case, the symptoms presented without a history of SO abuse, and no antipsychotics were administered during her hospitalization.…”

Section: Discussionmentioning

confidence: 99%

Mania-Like Reaction Secondary to Sodium Oxybate

Cárdenes-Moreno,

Pérez-Sagaseta de Ilurdoz,

Yelmo-Cruz

et al. 2024

J Clin Psychopharmacol

View full text Add to dashboard Cite

special attention among SSRI prescribers to both possibilities.This report aims to highlight an intriguing adverse effect of the SSRI fluoxetine, one that can prove quite distressing for patients and their families. Practitioners should be aware of the adverse effects that could lead to treatment nonadherence or could negatively affect mood and behavior by impacting a patient's sleep and/or personal image. Furthermore, this report draws attention to the incomplete understanding of SSRI therapy and its systemic impacts. We suggest further research examining the mechanism of this class of medications on micturition and urinary incontinence.

show abstract

Section: Discussionmentioning

confidence: 99%

Mania-Like Reaction Secondary to Sodium Oxybate

Cárdenes-Moreno,

Pérez-Sagaseta de Ilurdoz,

Yelmo-Cruz

et al. 2024

J Clin Psychopharmacol

View full text Add to dashboard Cite

show abstract

“…Additional support for the participation of GHBR and GHB in the pathogenesis of schizophrenia comes from case reports of psychosis and/or hallucinations after consumption of large amounts of GHB [57][58][59][60][61][62][63]. The number of these reports is not large, but it has been suggested that the prevalence of cases of psychosis caused by GHB is underestimated.…”

Section: Potential Effect Of Ghb and Ghb Receptors On The Developmentmentioning

confidence: 99%

“…GHB-induced psychoses have a clinical picture similar to schizophrenia: patients present with delusions (usually persecutory and religious) and auditory commenting hallucinations and/or pseudohallucinations [57][58][59][60][61][62][63]. Moreover, GHB overdosing is associated with the occurrence of negative symptoms similar to those found in schizophrenia: social withdrawal, reduced psychomotor drive, speech impoverishment, anhedonia, and anxiety [57,59,60,62]. Additionally, some studies report cases of suicide attempts and self-aggressive behavior [57,63].…”

Section: Potential Effect Of Ghb and Ghb Receptors On The Developmentmentioning

confidence: 99%

“…Dodatkowym źródłem mogącym świadczyć o wpływie GHBR oraz GHB w patogenezie schizofrenii są dostępne opisy przypadków występowania psychoz i/lub halucynacji po zażyciu dużych ilości GHB [57][58][59][60][61][62][63]. Liczba tych opisów nie jest duża, aczkolwiek sugeruje się, że liczba psychoz wywołana przez GHB jest niedoszacowana.…”

Section: Potencjalny Wpływ Receptorów Ghb I Ghb Na Rozwój Objawów Schunclassified

“…Psychozy wywołane przez GHB są w obrazie klinicznym podobne do schizofrenii: występują urojenia (zazwyczaj prześladowcze, a także religijne), halucynacje i/lub pseudohalucynajce o charakterze komentujących głosów [57][58][59][60][61][62][63]. Ponadto opisywane jest występowanie objawów negatywnych podobnych do tych występujących w schizofrenii: wycofanie społeczne, zmniejszenie napędu psychoruchowego, zubożenie mowy, anhedonia, lęk [57,59,60,62]. Dodatkowo w opisach przypadków może odnaleźć informacje o próbach samobójczych oraz zachowaniach autoagresywnych [57,63].…”

Section: Potencjalny Wpływ Receptorów Ghb I Ghb Na Rozwój Objawów Schunclassified

See 2 more Smart Citations

GHB receptors - a new trend in psychopharmacology?

Siembida

Karakuła

2018

Curr Probl Psychiatry

View full text Add to dashboard Cite

Introduction: Gamma-hydroxybutyric acid (GHB) is commonly known as a recreation drug or the so-called “date rape drug”. It is also used in medicine to treat narcolepsy and alcohol addiction. GHB has an affinity for two types of receptors: GABAB and the relatively recently discovered GHB receptors. GHB receptors were first cloned in 2003 in mice and then in 2007 in humans. So far, evidence has been presented for their impact on dopaminergic transmission, which may imply that they play a role in the pathogenesis of diseases such as schizophrenia. At the same time, it has been demonstrated that benzamide antipsychotic drugs have an affinity for GHB receptors, which is why it is postulated that some of the effects of these drugs may result precisely from this affinity. Aim: The study presents the current state of knowledge about GHB receptors and their potential role in the pathogenesis of schizophrenia, and discusses drugs which show an affinity for this receptor. Material and method: The literature review was based on a search of articles indexed between 1965 and 2018 in Medline, Google Scholar, ScienceDirect and Research Gate databases. The following search terms were used: GHB receptor, GHB, sulpiride, and amisulpride. Result and discussion: 1. It is possible that GHB receptors are involved in the pathogenesis of schizophrenia, although more research is needed in this area. 2. Part of the effects of some benzamide antipsychotic drugs (such as amisulpride) may be due to their affinity for GHB receptors.

show abstract

Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations

Morse,

Bogan,

Roy

et al. 2024

Neurol Ther

View full text Add to dashboard Cite

Introduction Low-sodium oxybate (LXB) is approved for treatment of narcolepsy in patients aged 7 years and older and treatment of idiopathic hypersomnia in adults. LXB contains the same active moiety with 92% less sodium than sodium oxybate (SXB). As the indication for oxybate treatment in patients with idiopathic hypersomnia is new and allows for individualized dosing optimization, guidance for beginning LXB treatment is needed. In particular, clinicians may benefit from guidance regarding treatment initiation, dosing/regimen options, potential challenges, and treatment expectations. Additionally, pharmacokinetic profiles differ slightly between both treatments, and further guidance on transitioning from SXB to LXB in patients with narcolepsy may aid clinicians. Methods An expert panel of five sleep specialists was convened to obtain consensus on recommendations for these topics using a modified Delphi process. Results Across two virtual meetings, the panel agreed on 31 recommendations with a high degree of consensus that fell into four overarching topics: (1) introducing LXB to patients; (2) initiating LXB for adult narcolepsy and idiopathic hypersomnia; (3) addressing challenges in using LXB; and (4) transitioning from SXB to LXB. The panel recommended that clinicians provide a clear overview of how LXB works for treating symptoms in narcolepsy or idiopathic hypersomnia, as appropriate for their patients, explain safety aspects, and set expectations prior to initiating LXB treatment. Strategies for initial dosing and regimen are provided. Strategies for adjusting the dose, regimen, timing, and consideration of individual factors were developed for specific instances in which patients may have trouble staying asleep or waking up, as well as guidance for addressing potential adverse events, such as nausea, dizziness, anxiety, and depression. Discussion points based on existing literature and clinical experience were included as relevant for each statement. Conclusion Clinicians may use this resource to guide LXB dosing optimization with patients. Supplementary Information The online version contains supplementary material available at 10.1007/s40120-024-00607-8.

show abstract

Psychosis in a 22-Year-Old Woman With Narcolepsy After Restarting Sodium Oxybate

Cited by 8 publications

References 16 publications

Mania-Like Reaction Secondary to Sodium Oxybate

Mania-Like Reaction Secondary to Sodium Oxybate

GHB receptors - a new trend in psychopharmacology?

Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations

Contact Info

Product

Resources

About